HomeEKSO • NASDAQ
add
Ekso Bionics Holdings Inc
Previous close
$0.72
Day range
$0.67 - $0.74
Year range
$0.67 - $3.13
Market cap
15.20M USD
Avg Volume
90.14K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD) | Sep 2024info | Y/Y change |
---|---|---|
Revenue | 4.13M | -10.38% |
Operating expense | 4.85M | -10.01% |
Net income | -2.07M | 38.42% |
Net profit margin | -50.18 | 31.30% |
Earnings per share | — | — |
EBITDA | -2.23M | 10.97% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Sep 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 8.29M | -16.55% |
Total assets | 29.21M | -6.33% |
Total liabilities | 14.34M | -9.96% |
Total equity | 14.87M | — |
Shares outstanding | 22.00M | — |
Price to book | 1.06 | — |
Return on assets | -23.48% | — |
Return on capital | -33.02% | — |
Cash Flow
Net change in cash
(USD) | Sep 2024info | Y/Y change |
---|---|---|
Net income | -2.07M | 38.42% |
Cash from operations | -2.28M | 32.09% |
Cash from investing | -8.00K | 52.94% |
Cash from financing | 4.69M | — |
Net change in cash | 2.41M | 171.42% |
Free cash flow | -1.11M | 57.80% |
About
Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk.
Ekso Bionics currently focuses in the health and industrial sectors.
The company's first commercially available health product was called EksoGT. Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community. Wikipedia
CEO
Founded
2005
Headquarters
Website
Employees
70